Core Viewpoint - Jinxin Fertility Group experienced a significant decline in stock price, reflecting challenges in its financial performance and market position [1][2]. Company Overview - Jinxin Fertility Group is a leading assisted reproductive services provider in China and the U.S., operating multiple hospitals and medical centers [1]. - The company ranked third in the Chinese assisted reproductive services market in 2018, conducting 20,958 in vitro fertilization cycles, with a market share of approximately 3.1%, and ranked first among non-state-owned institutions [1]. Financial Performance - For the mid-year report of 2025, Jinxin Fertility reported total revenue of 1.289 billion RMB and a net profit of -1.04 billion RMB [2]. - The company's profit attributable to shareholders for the fiscal year 2025 decreased by 648.24% year-on-year, resulting in a basic earnings per share of -0.39 RMB [2].

本文源自：财华网 【财华社讯】锦欣生殖(01951.HK)公布，截至2025年6月30日止六个月，收益约12.89亿元(人民币,下 同)，同比减少10.7%；拥有人应占亏损约10.4亿元，而上年拥有人应占利润约1.9亿元；每股基本亏损 0.39元。不派中期股息。 ...

Core Viewpoint - Jinxin Fertility (01951) reported a significant decline in financial performance, with a revenue drop of 10.75% year-on-year and a shift from profit to loss for shareholders, indicating challenges in the fertility services market in China [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 1.289 billion RMB, down 10.75% year-on-year [1] - Shareholder loss amounted to 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year, marking a significant turnaround [1] Contributing Factors - A decrease of approximately 8.3% in OPU cycles contributed to the revenue decline [1] - The proportion of IUI patients among ARS patients increased by about 10.04%, with IUI typically costing 80% to 85% less than IVF, impacting overall revenue [1] - Average single-cycle prices fell by 7% to 8% due to adjustments in national medical insurance [1] - A 24% decline in traditional childbirth volumes, driven by lower fertility willingness in China, led to reduced obstetric and related revenues [1] - The company has initiated new departments and businesses, which have contributed to revenue in those areas [1]

锦欣生殖(01951.HK)公布截至2025年6月30日的中期业绩，公司中期收益为12.89亿元人民币，同比下降 10.75%。股东应占亏损10.4亿元人民币，去年同期为溢利1.9亿元人民币。每股基本亏损0.39元人民币。 自2024年开展第三代试管婴儿以来，已服务超1500例患者。 收益减少的主要原因包括：OPU周期下降，IUI周期患者比例增加，国家医保调整导致平均单周期价格 下降，以及传统分娩量下降24%导致的产科收入减少。成都业务的取卵周期数同比减少6.1%，主要由于 初诊患者减少和IUI周期比例大幅增加。 ...

Group 1 - The company reported a revenue of 1.289 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 10.75% [1] - The company experienced a shareholder loss of 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year, indicating a significant shift from profit to loss [1] - The basic loss per share was reported at 0.39 RMB [1] Group 2 - The decline in revenue was primarily attributed to a decrease in OPU cycles by approximately 8.3%, an increase in the proportion of IUI patients by about 10.04%, and a reduction in average single-cycle prices by 7% to 8% due to national healthcare adjustments [1] - The traditional delivery volume decreased by approximately 24% due to lower fertility intentions in China, leading to a reduction in obstetric and related revenues [1] - The number of egg retrieval cycles in Chengdu decreased by 6.1% from 7,571 to 7,111, mainly due to a reduction in the number of first-time patients and a significant increase in the proportion of IUI cycles [1] Group 3 - Since the launch of third-generation IVF services in 2024, the company has served over 1,500 patients [2] - The company has introduced prenatal diagnosis and genetic counseling services to support women who conceive through IVF, enhancing the safety of pregnancies [2] - The company has developed an integrated model for IVF and maternity care, leveraging over 70 years of experience in women's and children's healthcare, with a VIP penetration rate of approximately 20.8% at the Sichuan Jinxin Xinan Hospital [2]

Group 1 - The company reported a revenue of 1.289 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 10.75% [1] - The company experienced a shareholder loss of 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year, indicating a significant shift from profit to loss [1] - The basic loss per share was reported at 0.39 RMB [1] Group 2 - The decline in revenue was primarily attributed to a decrease in OPU cycles by approximately 8.3%, an increase in the proportion of IUI patients by about 10.04%, and a reduction in average single-cycle prices by 7% to 8% due to national healthcare adjustments [1] - The traditional delivery volume decreased by about 24% due to lower fertility intentions in China, leading to a reduction in obstetric and related revenues [1] - The number of egg retrieval cycles in Chengdu decreased by 6.1% from 7,571 to 7,111, mainly due to a reduction in new patient numbers and a significant increase in IUI cycle proportions [1] Group 3 - Since the launch of third-generation IVF services in 2024, the company has served over 1,500 patients [2] - The company has introduced prenatal diagnosis and genetic counseling services to support women who conceive through IVF, enhancing the health of newborns [2] - The company has developed an integrated model for IVF and maternity care, leveraging over 70 years of experience in women's and children's healthcare, with a VIP penetration rate of approximately 20.8% at the Sichuan Jinxin Xinan Hospital [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited 錦 欣 生 殖 醫 療 集 團 有 限 公 司* （根據開曼群島法律註冊成立的有限公司） （股份代號：1951） 截至2025年6月30日止六個月 的業績公告 財務摘要 – 1 – ‧ 本集團截至2025年6月30日止六個月的收益約為人民幣1,288.6百萬元， 而截至2024年6月30日止六個月的收益約為人民幣1,443.8百萬元，較之 減少10.7%。 ‧ 本集團截至2025年6月30日止六個月的淨虧損約為人民幣1,044.1百萬元， 而截至2024年6月30日止六個月的本集團淨利潤約為人民幣190.3百萬元。 本集團截至2025年6月30日止六個月的擁有人應佔虧損約為人民幣1,039.9 百萬元，而截至2024年6月30日止六個月的本集團擁有人應佔利潤約為 人民幣189.7百萬元。 ‧ 本集團截至2025年6月30日止六個月的非國際財務 ...

Group 1 - The core viewpoint of the articles highlights the positive impact of the Federal Reserve's dovish stance on the Hong Kong pharmaceutical sector, leading to significant gains in related stocks and ETFs [1] - The Hong Kong pharmaceutical ETF (159718.SZ) has seen a year-to-date increase of nearly 88%, with notable stock performances from companies like Ping An Good Doctor (up 6.10%) and Jintai Holdings (up 5.90%) [1] - The Federal Reserve Chairman Powell's speech at the Jackson Hole conference indicated potential interest rate cuts, which has further boosted investor sentiment towards Chinese assets, particularly in the pharmaceutical sector [1] Group 2 - Recent catalysts for the innovative drug sector include upcoming industry conferences and the release of positive data from key products by companies like Dize and Fuhong Hanlin [2] - The adjustment of the medical insurance catalog and the promotion of commercial insurance policies are also seen as important catalysts for the industry [2] - The Hong Kong pharmaceutical ETF is described as a balanced investment tool that includes not only innovative drugs but also CXO, internet healthcare, and innovative medical devices, making it a convenient option for investors [2]

8月25日，锦欣生殖披露2025财年中报。 8月25日，锦欣生殖(01951)盘中上涨5.28%，截至10:17，报3.39元/股，成交9395.98万元。 锦欣生殖医疗集团有限公司是中美领先的辅助生殖服务机构，拥有和经营多家医院和医疗中心，主要提 供辅助生殖服务及相关治疗。根据弗若斯特沙利文报告，2018年，公司在中国辅助生殖服务市场中排名 第三，进行了20,958个体外受精取卵周期，市场份额约为3.1%，在非国有辅助生殖服务机构中排名第 一。 截至2024年年报，锦欣生殖营业总收入28.12亿元、净利润2.83亿元。 本文源自：金融界 作者：行情君 ...

Group 1 - The core viewpoint of the article highlights the performance of the Sci-Tech Chip ETF (588290), which opened with a gain of 1.43% at 2.051 yuan [1] - The top holdings of the Sci-Tech Chip ETF include companies such as SMIC, which rose by 1.95%, and Haiguang Information, which increased by 5.34% [1] - The fund's performance benchmark is the Shanghai Stock Exchange Sci-Tech Board Chip Index, managed by Huaan Fund Management Co., with a return of 98.32% since its inception on September 30, 2022, and a return of 32.13% over the past month [1]